RESUMEN
Honduran dwarf mistletoe (Arceuthobium hondurense Hawksw. & Wiens) has only been found in four locations in Honduras: west of Zamorano, east of Lepaterique, Cusuco National Park, and Celaque National Park (1,2). At one time it was believed that this mistletoe could be in danger of extinction (1). However, it has also been reported in two locations in Chiapas, Mexico (3). In December 2000, ≈1 km north of Suchixtepec, Oaxaca, Mexico, near Route 175 (elevation 2,770 m), we collected a dwarf mistletoe parasitizing Pinus tecunumanii (Schw.) Eguiluz et Perry that was morphologically similar to A. hondurense (1). This population initially had been classified as A. nigrum Hawksw. & Wiens (1), but is now classified as A. hondurense based on morphology (male flower color and stigma length) (1) and analysis of nuclear rDNA internal transcribed spacer (ITS) sequences from Honduras (GenBank Accession No. AF325969) and Oaxaca (GenBank Accession No. AY055215). A comparison of these two A. hondurense ITS sequences indicated they are very closely related to each other, whereas both are distinct from A. nigrum (GenBank Accession No. L25693). Specimens of A. hondurense from Oaxaca were deposited at the Deaver Herbarium, Northern Arizona University, Flagstaff. To our knowledge, this is the first report of A. hondurense in Oaxaca, Mexico, and extends its known distribution west across the Isthmus of Tehuantepec from central Chiapas by ≈400 km. References: (1) F. G. Hawksworth and D. Wiens. Dwarf Mistletoes: Biology, Pathology, and Systematics. USDA Agric. Handb. 709, 1996. (2) R. Mathiasen et al. Phytologia 85:268, 1998. (3) R. Mathiasen et al. Plant Dis. 85:444, 2001.
RESUMEN
Concern that salicylates may play a role in the pathogenesis of Reye syndrome has raised the question of whether children receiving salicylate therapy for connective tissue disease are at risk for development of Reye syndrome. Of 176 patients with biopsy-confirmed Reye syndrome studied between January 1969 and June 1983, six had connective tissue disease at the time of development of Reye syndrome, and all six were receiving salicylates. Compared with the general population, children receiving salicylate therapy for connective tissue disease may be at increased risk for the development of Reye syndrome.